Regulatory Watch · June 2026
Sandoz files for generic tirzepatide.
The clock starts — not the launch.
FDA has accepted two Sandoz ANDAs for review for tirzepatide (Mounjaro/Zepbound). Acceptance marks the beginning of a multi-stage regulatory and patent process — not an imminent generic launch.
What has to happen next
Why the FDA filing isn't the finish line
Relevant regulatory precedents
Sandoz is not entering unfamiliar territory. Several complex generic approvals demonstrate that scientifically challenging products can navigate regulatory review and patent litigation.
An ANDA filing is the starting point, not the finish line. The timing of generic tirzepatide will ultimately depend on FDA review, patent litigation, settlements, and court outcomes — not FDA acceptance alone.
What this means for India
The Sandoz ANDA filing is specific to the US market. In India, tirzepatide (Mounjaro) is currently marketed by Eli Lilly. Indian generic entry depends on India-specific patent status — which differs materially from the US Orange Book listings that govern the Sandoz filing.
Indian patent law, compulsory licensing provisions, and DCGI regulatory requirements would each play a role in any domestic generic tirzepatide pathway — independent of what happens in US courts.
Compare tirzepatide brand prices in India →Frequently Asked Questions
Has Sandoz received approval to sell generic tirzepatide?
No. FDA has accepted Sandoz's ANDAs for review — this means the applications are complete enough to begin evaluation. Acceptance is not approval. FDA must complete its review, and any patent litigation must be resolved before a generic can launch.
What is a 30-month stay in ANDA proceedings?
If Eli Lilly files a timely patent infringement suit after receiving Paragraph IV notice from Sandoz, the Hatch-Waxman Act allows FDA approval to be delayed for up to 30 months — or until the court rules on the patent, whichever comes first. This is a statutory provision, not automatic.
When does tirzepatide's primary patent expire?
The primary compound patent for tirzepatide expires in 2036 per FDA Orange Book listings. Additional formulation, device, and method-of-use patents may also influence the timing of generic entry.
What does this mean for tirzepatide prices in India?
The Sandoz ANDA filing is specific to the US market and does not directly affect Indian pricing. Indian generic entry would depend on India-specific patent status, DCGI requirements, and compulsory licensing provisions — all separate from US proceedings.
More GLP-1 and tirzepatide intelligence from RxIntel
Sources & Editorial Note
- → Sandoz announcement (June 2026): ANDA filing for tirzepatide
- → FDA Orange Book & Hatch–Waxman filing framework
- → 21 U.S.C. §355(j) — statutory 30-month stay provisions
- → FDA Orange Book & USPTO — tirzepatide patent listings
- → FDA GDUFA guidance — 10-month review goal timeline
This is an informational summary, not legal advice. Verify all dates, patent listings, and regulatory status against current FDA and court records before making commercial or legal decisions.